1-3 of 3
P. S. Cohen
Close
Sort by
Journal Articles

Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Francis Giles, C. Schiffer, H. Kantarjian, T. Fischer, R. Paquette, D. M. Pelov, D. J. Resta, P. S. Cohen, Y. F. Wang, R. Stone
Journal: Blood
Blood (2004) 104 (11): 262.
https://doi.org/10.1182/blood.V104.11.262.262
Published: 2004
Journal Articles

Clinical Course and Significance of the Novel FLT3-Y842C Mutation in a Patient with AML Treated with PKC412 Monotherapy.

T. Kindler, F. Breitenbuecher, S. Kasper, E. Estey, F. Giles, E. Feldman, G. Ehninger, G. Schiller, V. Klimek, S. D. Nimer, A. Gratwohl, C. Choudhary, C. Mueller-Tidow, H. Serve, H. Gschaidmeier, P. S. Cohen, C. Huber, T. Fischer
Journal: Blood
Blood (2004) 104 (11): 2537.
https://doi.org/10.1182/blood.V104.11.2537.2537
Published: 2004
Journal Articles

Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.

F. Heidel, F. Breitenbuecher, T. Kindler, F. K. Solem, B. Carius, H.-M. Thiede, P. S. Cohen, J. Roesel, E. H. Estey, E. Feldman, G. Ehninger, G. J. Schiller, V. Klimek, S. Nimer, D. DeAngelo, F. Giles, R. M. Stone, C. Huber, T. Fischer
Journal: Blood
Blood (2004) 104 (11): 454.
https://doi.org/10.1182/blood.V104.11.454.454
Published: 2004